MIR650

Summary

MIR650 (microRNA 650, HGNC:32906) is a microRNA gene on chromosome 22q11.22.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 723778 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32906
Approved symbol	MIR650
Name	microRNA 650
Location	22q11.22
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-650
Ensembl gene	ENSG00000284049
Ensembl biotype	miRNA
OMIM	615379
Entrez	723778
RNAcentral	URS000075CEFF — miRNA, 96 nt, 2 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385101

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385101 — 1 exons

Exon	Start	End
ENSE00001806979	22822776	22822871

Expression profiles

Bgee: expression breadth broad, 90 present calls, max score 91.05.

Top tissues by expression

90 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	91.05	gold quality
vermiform appendix	UBERON:0001154	89.85	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	86.03	gold quality
lymph node	UBERON:0000029	83.74	gold quality
small intestine	UBERON:0002108	80.60	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.52	gold quality
minor salivary gland	UBERON:0001830	79.23	gold quality
bone marrow	UBERON:0002371	79.20	gold quality
saliva-secreting gland	UBERON:0001044	79.18	gold quality
blood	UBERON:0000178	79.05	gold quality
transverse colon	UBERON:0001157	78.91	gold quality
colon	UBERON:0001155	78.36	gold quality
fundus of stomach	UBERON:0001160	77.76	gold quality
stomach	UBERON:0000945	77.55	gold quality
spleen	UBERON:0002106	77.20	gold quality
body of stomach	UBERON:0001161	76.66	gold quality
leukocyte	CL:0000738	75.46	gold quality
rectum	UBERON:0001052	73.86	gold quality
monocyte	CL:0000576	73.84	gold quality
granulocyte	CL:0000094	73.79	gold quality
left uterine tube	UBERON:0001303	73.18	gold quality
muscle layer of sigmoid colon	UBERON:0035805	72.61	gold quality
liver	UBERON:0002107	72.19	gold quality
left coronary artery	UBERON:0001626	72.17	gold quality
gastrocnemius	UBERON:0001388	71.31	gold quality
right lobe of liver	UBERON:0001114	71.03	gold quality
right lung	UBERON:0002167	70.58	gold quality
thoracic mammary gland	UBERON:0005200	70.56	gold quality
tonsil	UBERON:0002372	70.45	gold quality
urinary bladder	UBERON:0001255	70.42	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.24

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 27)

• over-expression of miR-650 in gastric cancer may promote proliferation and growth of cancer cells, at least partially through directly targeting ING4. (PMID:20381459)
• these results suggest that NDRG2 expression is regulated by promoter methylation and miR-650 in human colorectal cancer cells. (PMID:21352815)
• higher expression of miR-650 is associated with a favorable CLL prognosis and influences the proliferation capacity of B cells. (PMID:22234685)
• Data suggested that miR-650 is correlated with the pathogenesis of hepatocellular carcinoma (HCC) and is involved in the HCC tumorigenesis process by inhibiting the expression of ING4. (PMID:22767438)
• miR-650 is a novel prognostic marker in LAD and its expression is a potential indicator of chemosensitivity to docetaxel-based chemotherapy regimen (PMID:23991130)
• High miR-650 expression was associated with glioma. (PMID:24062138)
• Suppression of CSR1 expression is a novel mechanism critical for the oncogenic activity of miR-650. (PMID:25956032)
• these findings reveal a novel link between miR-650 and the innate immune response in human monocyte-derived dendritic cells (PMID:26460926)
• This is the first evidence linking miR-650 and breast cancer (PMID:28101578)
• MiR-650 could inhibit the proliferation, migration and invasion of rheumatoid arthritis synovial fibroblasts through targeted regulation of AKT2 expression. (PMID:28129626)
• Our results highlight the potential of miR-650 as a prognostic prediction biomarker and therapeutic target in non-metastatic CRC via inhibition of the AKT2/GSK3beta/E-cadherin pathway. (PMID:28548936)
• Low miR650 expression is associated with Acute myeloid leukemia. (PMID:28574132)
• These results suggest that the upregulation of miR-650 contributes to the development of acute renal allograft rejection by suppression of BCL11B, which leads to apoptosis and inflammatory responses. Thus, miR-650 and BCL11B may represent potential therapeutic targets for the prevention of acute renal allograft rejection. (PMID:29039465)
• We observed the knockdown of NDRG2 with miR-28-5p and miR-650 inhibitors inducing CLL cell apoptosis, yet found no increased apoptosis rates in patients with p53 aberrations following transfection with the above miRNAs inhibitors. (PMID:30348117)
• miR-650 levels were largely up-regulated in hepatocellular carcinoma (HCC) tissues, and that the increased expression was closely associated with the adverse clinical features of HCC patients. Additionally, the expression of LATS2, which was identified as a direct target of miR-650, can counteract the effects of miR-650 in HCC. (PMID:30481780)
• Low MiR-650 expression in glioma cells promotes tumor cell proliferation by up-regulating the expression of FAM83F. (PMID:30556880)
• These results suggest that miR-650/PPP2CA axis could be modulated to interfere with motile ability of thyroid carcinoma cells (PMID:30927143)
• Overexpression of NLRP6 in Caco-2 and IEC-6cells suppress the increase apoptosis induced by miR-650 overexpression. (PMID:31399193)
• Low apolipoprotein E (apoE) and mir-650 plasma concentrations were risk factors for developing Alzheimer’s disease (AD) and were particularly pronounced in severe dementia cognitive functions (PMID:31556571)
• NF-kappaB-mediated miR-650 plays oncogenic roles and activates AKT/ERK/NF-kappaB pathways by targeting RERG in glioma cells. (PMID:32986146)
• A Bioinformatic Pipeline Places STAT5A as a miR-650 Target in Poorly Differentiated Aggressive Breast Cancer. (PMID:33086498)
• Upregulation of microRNA-650 by PBX1 is correlated with the development of Helicobacter pylori-associated gastric carcinoma. (PMID:33147052)
• Circ-AFF2/miR-650/CNP axis promotes proliferation, inflammatory response, migration, and invasion of rheumatoid arthritis synovial fibroblasts. (PMID:33653372)
• DICER-AS1 functions as competing endogenous RNA that targets CSR1 by sponging microRNA-650 and suppresses gastric cancer progression. (PMID:34586953)
• Knockdown of circ_0025908 inhibits proliferation, migration, invasion, and inflammation while stimulates apoptosis in fibroblast-like synoviocytes by regulating miR-650-dependent SCUBE2. (PMID:35904110)
• MicroRNA-650 suppresses KLF12 expression to regulate growth and metastasis of human ovarian cancer cells. (PMID:36272152)
• LINC01002 Targets miR-650/FLNA Pathway to Suppress Prostate Cancer Progression. (PMID:37040719)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.